Metabolic dysfunction-associated steatotic liver disease (MASLD) has a strong heritable component, and genome-wide association cohort studies are highlighting the major genetic determinants of this condition. A meta-analysis of these databases has now enabled expansion of the list of the inherited variants that modulate the risk of MASLD. The identification of new MASLD risk loci is improving comprehension of disease pathogenesis and individual risk stratification, and also enabling the identification of novel therapeutic targets and disease subtypes that might ultimately lead to a precision medicine approach.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. https://doi.org/10.1016/j.jhep.2023.06.003 (2023).
Trépo, E. & Valenti, L. Update on NAFLD genetics: from new variants to the clinic. J. Hepatol. 72, 1196–1209 (2020).
Sveinbjornsson, G. et al. Multiomics study of nonalcoholic fatty liver disease. Nat. Genet. 54, 1652–1663 (2022).
Chen, Y. et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat. Genet. 55, 1640–1650 (2023).
Teo, K. et al. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis. J. Hepatol. 74, 20–30 (2021).
Cherubini, A. et al. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat. Med. https://doi.org/10.1038/s41591-023-02553-8 (2023).
Bianco, C. et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J. Hepatol. 74, 775–782 (2021).
Dongiovanni, P. et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J. Intern. Med. 283, 356–370 (2018).
Stender, S. et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat. Genet. 49, 842–847 (2017).
Vujkovic, M. et al. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat. Genet. 54, 761–771 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
L.V.C.V. has received speaking fees from Viatris and Novo Nordisk, consulted for Novo Nordisk, Pfizer, Boehringer Ingelheim, and Resalis, and received unrestricted grant support from Gilead. V.M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Valenti, L.V.C., Moretti, V. Implications of the evolving knowledge of the genetic architecture of MASLD. Nat Rev Gastroenterol Hepatol 21, 5–6 (2024). https://doi.org/10.1038/s41575-023-00866-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00866-0
